European Journal of Cancer
Volume 44, Issue 17 , Pages 2555-2572, November 2008

Inoperable colorectal liver metastases: A declining entity?

Department of Hepatobiliary and Upper Gastrointestinal Surgery, The Queen Elizabeth Hospital, 28 Woodville Road, Adelaide, SA 5011, Australia

Received 5 June 2008; received in revised form 14 July 2008; accepted 17 July 2008. published online 28 August 2008.

Abstract 

Background

Untreated colorectal liver metastases (CLMs) have a dismal prognosis. Surgery remains the gold standard of treatment, but many patients will have inoperable disease at presentation. Until recently, the outlook for such patients was bleak. The purpose of this review was to report on available options in the treatment CLMs, which would be considered unresectable by conventional evaluation.

Methods

Inclusion criteria were articles published in English-language journals reporting on either retrospective or prospective cohorts of patients undergoing treatment for conventionally inoperable CLM. Main outcome measures were survival, resectability rates, morbidity and mortality following treatment of the patients’ disease.

Results

Improved chemotherapy regimes and other innovative treatments have opened up new options for such patients and may even render conventionally inoperable disease resectable. The aim of treatment should be down-staging of metastases to achieve resectability, however, other treatments such as ablation may be also be used (either alone or in conjunction with resection).

Conclusion

A nihilistic attitude to the patient with seemingly inoperable liver metastases should be discouraged. Discussion of such patients at multi-disciplinary meetings is essential in order to plan and monitor treatments.

Keywords: Colorectal hepatic metastases, Ex vivo resection, Chemotherapy, Hepatic artery infusion, Radiotherapy, Ablation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(08)00576-5

doi:10.1016/j.ejca.2008.07.028

European Journal of Cancer
Volume 44, Issue 17 , Pages 2555-2572, November 2008